Related references
Note: Only part of the references are listed.Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART
Brian C. Zanoni et al.
AIDS (2011)
Paradoxically elevated efavirenz concentrations in HIV/tuberculosis-coinfected patients with CYP2B6 516TT genotype on rifampin-containing antituberculous therapy
Awewura Kwara et al.
AIDS (2011)
Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting
Grant Theron et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Treatment 2.0: catalysing the next phase of scale-up
Gottfried Hirnschall et al.
LANCET (2011)
Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study
Catharina C. Boehme et al.
LANCET (2011)
TB and HIV integration: obstacles and possible solutions to implementation in South Africa
Marian Loveday et al.
TROPICAL MEDICINE & INTERNATIONAL HEALTH (2011)
HIV Coinfection in Multidrug- and Extensively Drug-Resistant Tuberculosis Results in High Early Mortality
Neel R. Gandhi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis Patients
Andreas H. Diacon et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Running a tightrope: Regulatory challenges in the development of antiretrovirals
Lisa K. Naeger et al.
ANTIVIRAL RESEARCH (2010)
Global tuberculosis drug development pipeline: the need and the reality
Zhenkun Ma et al.
LANCET (2010)
Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study
Keertan Dheda et al.
LANCET (2010)
Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs
Frederick L. Altice et al.
LANCET (2010)
Biomarkers for tuberculosis disease activity, cure, and relapse
Patrick Peter John Phillips et al.
LANCET INFECTIOUS DISEASES (2010)
Biomarkers for tuberculosis disease activity, cure, and relapse
Robert S. Wallis et al.
LANCET INFECTIOUS DISEASES (2010)
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Catharina C. Boehme et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Timing of Initiation of Antiretroviral Drugs during Tuberculosis Therapy
Salim S. Abdool Karim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical experience with the combined use of lopinavir/ritonavir and rifampicin
Rafaela F. A. L'homme et al.
AIDS (2009)
Substitution of Moxifloxacin for Isoniazid during Intensive Phase Treatment of Pulmonary Tuberculosis
Susan E. Dorman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial
Marcus B. Conde et al.
LANCET (2009)
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Andreas H. Diacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Clinical impact of patient population differences and genomic variation in efavirenz therapy
Jennifer King et al.
AIDS (2008)
Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis
R. Rustomjee et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy
Andrew Boulle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Exogenous Reinfection as a Cause of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Rural South Africa
Jason R. Andrews et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Design issues in pivotal drug trials for drug sensitive tuberculosis (TB)
Andrew J. Nunn et al.
TUBERCULOSIS (2008)
Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis
Karen Cohen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
lPostpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005
Amita Gupta et al.
CLINICAL INFECTIOUS DISEASES (2007)
New approaches and emerging technologies in the diagnosis of childhood tuberculosis
Ben J. Marais et al.
PAEDIATRIC RESPIRATORY REVIEWS (2007)
Viral hepatitis in HIV infection
Margaret James Koziel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa
Stephen D. Lawn et al.
AIDS (2007)
Multidrug-resistant tuberculosis management in resource-limited settings
Eva Nathanson et al.
EMERGING INFECTIOUS DISEASES (2006)
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis
William J. Burman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
Acquired rifamycin resistance with twice-weekly treatment of HIV-related tuberculosis
W Burman et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2006)
The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis
DC Perlman et al.
CLINICAL INFECTIOUS DISEASES (2005)
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis
M Weiner et al.
CLINICAL INFECTIOUS DISEASES (2005)
Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment
R van Hest et al.
CLINICAL INFECTIOUS DISEASES (2004)
Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens
WW Yew et al.
CHEST (2000)
Share Paper
